LTR Pharma Executes Definitive US Distribution Agreement With Shed Holdings for ROXUS, Shares Up 11%

MT Newswires Live
07/17

LTR Pharma (ASX:LTP) executed a definitive telehealth distribution agreement with Shed Holdings, a US direct-to-consumer telehealth platform, converting a previously disclosed binding term sheet into a definitive commercial agreement for the planned US commercialization of ROXUS, according to a Friday Australian bourse filing.

The company said Shed has committed to support the delivery of not less than 150,000 ROXUS units during the first 12 months following commercial launch.

ROXUS is the company's fast-acting intranasal spray for the treatment of erectile dysfunction.

The company's shares rose 11% in recent Friday trade.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10